▟ Vinebot intrinsic value, daily

← back

BDX Becton Dickinson

healthcare · valued with opus medium conviction · deep-dived 2026-10-08

SELL
Intrinsic value$68.21
Price (at call)$180.16
Margin of safety -62.1%
vs market (rating basis) -28.8%

Durable hospital consumables franchise priced near fair value; upside needs GAAP margins actually catching adjusted ones.

The story

Becton Dickinson is a scaled medical-technology franchise in syringes, needles, IV catheters, infusion pumps (Alaris), and medication management. It has razor/razor-blade consumable lock-in with hospitals. After separating Biosciences & Diagnostics into the Waters transaction, it is a mature, mid-single-digit grower. Reported GAAP margins are depressed by heavy acquisition amortization, restructuring, and quality remediation, which masks underlying adjusted margins in the low-to-mid 20s.

Growth stays at roughly 3-5%, matching BD's mature consumables mix and modest portfolio shrink from the separation. The margin target of 19% sits between the depressed 11-12% GAAP figure and the ~25% adjusted figure: it treats part of the amortization and the recurring restructuring as real economic costs. The reported 0.47 sales-to-capital is inflated by goodwill, so I use 1.0 as the incremental figure because organic reinvestment is far lighter. Beta of 0.85 reflects defensive hospital demand, partly offset by $18.5B of net debt.

Value drivers

Revenue growth (Y1)3.0%
Terminal growth3.0%
Forecast horizon7y
Target operating margin19.0%
Years to target margin5
Sales-to-capital1.00
Beta0.85
Failure probability2.0%
Cost of capital (WACC)9.4%
Terminal WACC9.9%

Valuation bridge

PV of explicit FCFF13.25B
PV of terminal value24.25B
Equity value18.58B
÷ shares → per share$68.21

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 21.47B 3.0% 11.8% 2.26B 625.20M 1.64B 1.49B
2 22.11B 3.0% 13.6% 2.68B 643.96M 2.04B 1.70B
3 22.77B 3.0% 15.4% 3.13B 663.27M 2.47B 1.88B
4 23.46B 3.0% 17.2% 3.60B 683.17M 2.92B 2.04B
5 24.16B 3.0% 19.0% 4.09B 703.67M 3.39B 2.17B
6 24.88B 3.0% 19.0% 4.22B 724.78M 3.49B 2.04B
7 25.63B 3.0% 19.0% 4.34B 746.52M 3.60B 1.92B

Key risks

  • Alaris pump and other quality/FDA remediation issues recur, delaying margin recovery
  • China volume-based procurement and US hospital capex pressure weigh on pricing and volumes
  • High leverage after the separation limits flexibility if integration or restructuring costs keep recurring

Catalysts

  • Clean execution post-Waters separation with debt paydown and a simplified, higher-margin RemainCo
  • GAAP margins converging toward adjusted levels as amortization rolls off and restructuring ends

History

DatePriceIntrinsicMoSRating
2026-10-08$180.16 $68.21 -62.1% SELL
2026-08-19$180.77 $0.00 -100.0% STRONG SELL
2026-06-29$155.92 $49.14 -68.5% SELL
2026-06-23$143.94 $70.76 -50.8% HOLD